Gilead’s Covid-19 Drug Deal: Analysts Don’t See Financial Gains For Generic Firms
A magnified coronavirus germ is displayed on a desktop computer monitor during coronavirus patient sample detection tests at a virology research labs. (Photographer: Geert Vanden Wijngaert/Bloomberg)

Gilead’s Covid-19 Drug Deal: Analysts Don’t See Financial Gains For Generic Firms

Gilead Sciences Inc. signed non-exclusive licensing pacts with five generic drugmakers in India and Pakistan to make and supply remdesivir, a potential treatment for Covid-19, in 127 countries.The ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.